↓ Skip to main content

Real-world evaluation of compliance and preference in Alzheimer’s disease treatment

Overview of attention for article published in Clinical Interventions in Aging, November 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (85th percentile)
  • High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

news
1 news outlet
twitter
3 X users
facebook
1 Facebook page

Citations

dimensions_citation
9 Dimensions

Readers on

mendeley
76 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Real-world evaluation of compliance and preference in Alzheimer’s disease treatment
Published in
Clinical Interventions in Aging, November 2015
DOI 10.2147/cia.s85319
Pubmed ID
Authors

Ming-Chyi Pai, Hany Aref, Nazem Bassil, Nagaendran Kandiah, Jae-Hong Lee, AV Srinivasan, Shelley diTommaso, Ozgur Yuksel

Abstract

Rivastigmine transdermal patch has shown higher caregiver satisfaction and greater preference than oral formulation in patients with Alzheimer's disease. However, there is limited literature available related to caregiver preference or treatment compliance in real-world clinical settings. To date, no such data are available from Asia and the Middle East, which account for a sizeable proportion of patients with Alzheimer's disease. The objective of this study was to evaluate treatment preference and compliance with oral and transdermal medications in daily clinical practice in an ethnically diverse patient population from Asia and the Middle East with mild-to-moderate Alzheimer's disease. RECAP (Real-world Evaluation of Compliance And Preference in the treatment of Alzheimer's disease) was a 24-week, multicenter, prospective, noninterventional study. Two treatment cohorts were observed during the study: oral (cholinesterase inhibitors or memantine) and transdermal (rivastigmine patch). Caregiver preference, physician preference, and patient compliance were evaluated at week 24. A total of 978 of 1,931 enrolled patients (mean age: 72.8 years; 50.5% female) were in the transdermal cohort. For patients with exposure to both oral and transdermal monotherapy (n=330), a significant caregivers' preference for the transdermal monotherapy was observed (82.7%; P<0.0001). Of the 89 participating physicians, 71 indicated preference for transdermal monotherapy. Patient compliance was also significantly higher for transdermal than oral monotherapy (P<0.0001). Our study showed higher caregiver and physician preference and greater patient compliance with transdermal monotherapy in daily practice.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 76 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Russia 1 1%
Brazil 1 1%
Egypt 1 1%
Unknown 73 96%

Demographic breakdown

Readers by professional status Count As %
Researcher 7 9%
Student > Bachelor 7 9%
Student > Postgraduate 5 7%
Student > Master 5 7%
Student > Doctoral Student 5 7%
Other 18 24%
Unknown 29 38%
Readers by discipline Count As %
Medicine and Dentistry 7 9%
Nursing and Health Professions 7 9%
Psychology 7 9%
Social Sciences 4 5%
Pharmacology, Toxicology and Pharmaceutical Science 3 4%
Other 15 20%
Unknown 33 43%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 March 2016.
All research outputs
#3,138,906
of 25,374,917 outputs
Outputs from Clinical Interventions in Aging
#331
of 1,968 outputs
Outputs of similar age
#42,353
of 294,812 outputs
Outputs of similar age from Clinical Interventions in Aging
#6
of 49 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,968 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.1. This one has done well, scoring higher than 82% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 294,812 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 85% of its contemporaries.
We're also able to compare this research output to 49 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.